Merck & Co.
AWARDS
NEWS
Moderna Therapeutics and Merck expanded their 2016 collaboration deal to develop and commercialize personalized messenger RNA (mRNA) cancer vaccines. The new deal will include mRNA cancer vaccines that share antigens, including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine.
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
Scandals are nothing new in any industry. The pharmaceutical and biotech industry are certainly no strangers to scandals – just ask convicted scandal-magnet Martin Shkreli.
Ahead of June’s annual American Society of Clinical Oncology meeting Merck said this morning that its Phase III lung cancer trial met a pre-specified secondary endpoint of overall response rate (ORR) in an early cohort of participants at an interim analysis.
As Biogen turns 40 years old, some biotech insiders and analysts seem to be concerned that the Boston-based pharmaceutical company has too many eggs in one developmental basket.
Sanofi and Regeneron made a deal with pharmacy benefits manager Express Scripts for their Praluent, making it the exclusive PCSK9 inhibitor on their national formulary, essentially locking Amgen’s Repatha out of that market segment.
JOBS
IN THE PRESS